Leslie K. Ballas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leslie K. Ballas has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Susan Groshen
Department of Preventative Medicine Keck School of Medicine University of Southern CA Los Angeles CA USA
5 shared publicationsLingyun Ji
University of Southern California, Keck School of Medicine, Department of Preventative Medicine, Los Angeles, California
3 shared publicationsSiamak Daneshmand
Department of Urology Keck School of Medicine University of Southern California Los Angeles CA USA
3 shared publications- Amar U. Kishan
Department of Radiation Oncology, University of California Los Angeles, Los Angeles, USA
2 shared publications Andre Abreu
Department of Urology, University of Southern California Keck School of Medicine, Los Angeles, California
2 shared publications- Andrew R. Barsky
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
2 shared publications
Latest Publications
- 27 December 2024
- Published by Elsevier in Practical Radiation Oncology
- Vol. 15 (4) , e350-e361
Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study
- 27 December 2024
- Published by Elsevier in Practical Radiation Oncology
- Vol. 15 (4) , e350-e361
Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study
- 12 December 2024
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 35 (1) , 87-98
Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection
- 12 December 2024
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 35 (1) , 87-98
Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection
- 29 October 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (4) , 1026-1038
Irradiated Bone Marrow Volume is Associated With Hematologic Toxicity in Patients With Multiple Myeloma
- 29 October 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (4) , 1026-1038
Irradiated Bone Marrow Volume is Associated With Hematologic Toxicity in Patients With Multiple Myeloma
- 1 January 2024
- Published by Springer Nature
- p. 219-242
Target Volume Delineation for Plasmacytoma and Multiple Myeloma
- 1 January 2024
- Published by Springer Nature
- p. 219-242
Target Volume Delineation for Plasmacytoma and Multiple Myeloma
- 19 November 2023
- Published by Elsevier in Practical Radiation Oncology
- Vol. 14 (2) , e141-e149
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry
- 19 November 2023
- Published by Elsevier in Practical Radiation Oncology
- Vol. 14 (2) , e141-e149
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry
- Open Access
Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial
Purpose: To evaluate geometric variations of patients receiving stereotactic body radiotherapy (SBRT) after radical prostatectomy and the dosimetric benefits of stereotactic MRI guided adaptive radiotherapy (SMART) to compensate for these variations. Materials/Methods: The CTV and OAR were contoured on 55 MRI setup scans of 11 patients treated with an MR-LINAC and enrolled in a phase II trial of post-prostatectomy SBRT. All patients followed institutional bladder and rectum preparation protocols and received five fractions of 6−6.8 Gy to the prostate bed. Interfractional changes in volume were calculated and shape deformation was quantified by the Dice similar coefficient (DSC). Changes in CTV-V95%, bladder and rectum maximum dose, V32.5Gy and V27.5Gy were predicted by recalculating the initial plan on daily MRI. SMART was retrospectively simulated if the predicted dose exceeded pre-set criteria. Results: The CTV volume and shape remained stable with a median volumetric change of 3.0% (IQR −3.0% to 11.5%) and DSC of 0.83 (IQR 0.79 to 0.88). Relatively large volumetric changes in bladder (median −24.5%, IQR −34.6% to 14.5%) and rectum (median 5.4%, IQR − 9.7% to 20.7%) were observed while shape changes were moderate (median DSC of 0.79 and 0.73, respectively). The median CTV-V95% was 98.4% (IQR 94.9% to 99.6%) for the predicted doses. However, SMART would have been deemed beneficial for 78.2% of the 55 fractions based on target undercoverage (16.4%), exceeding OAR constraints (50.9%), or both (10.9%). Simulated SMART improved the dosimetry and met dosimetric criteria in all fractions. Moderate correlations were observed between the CTV-V95% and target DSC (R2 = 0.73) and bladder mean dose versus volumetric changes (R2 = 0.61). Conclusions: Interfractional dosimetric variations resulting from anatomic deformation are commonly encountered with post-prostatectomy RT and can be mitigated with SMART.
Open AccessInterfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial
Purpose: To evaluate geometric variations of patients receiving stereotactic body radiotherapy (SBRT) after radical prostatectomy and the dosimetric benefits of stereotactic MRI guided adaptive radiotherapy (SMART) to compensate for these variations. Materials/Methods: The CTV and OAR were contoured on 55 MRI setup scans of 11 patients treated with an MR-LINAC and enrolled in a phase II trial of post-prostatectomy SBRT. All patients followed institutional bladder and rectum preparation protocols and received five fractions of 6−6.8 Gy to the prostate bed. Interfractional changes in volume were calculated and shape deformation was quantified by the Dice similar coefficient (DSC). Changes in CTV-V95%, bladder and rectum maximum dose, V32.5Gy and V27.5Gy were predicted by recalculating the initial plan on daily MRI. SMART was retrospectively simulated if the predicted dose exceeded pre-set criteria. Results: The CTV volume and shape remained stable with a median volumetric change of 3.0% (IQR −3.0% to 11.5%) and DSC of 0.83 (IQR 0.79 to 0.88). Relatively large volumetric changes in bladder (median −24.5%, IQR −34.6% to 14.5%) and rectum (median 5.4%, IQR − 9.7% to 20.7%) were observed while shape changes were moderate (median DSC of 0.79 and 0.73, respectively). The median CTV-V95% was 98.4% (IQR 94.9% to 99.6%) for the predicted doses. However, SMART would have been deemed beneficial for 78.2% of the 55 fractions based on target undercoverage (16.4%), exceeding OAR constraints (50.9%), or both (10.9%). Simulated SMART improved the dosimetry and met dosimetric criteria in all fractions. Moderate correlations were observed between the CTV-V95% and target DSC (R2 = 0.73) and bladder mean dose versus volumetric changes (R2 = 0.61). Conclusions: Interfractional dosimetric variations resulting from anatomic deformation are commonly encountered with post-prostatectomy RT and can be mitigated with SMART.
- Open Access
- 21 May 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (2) , 725-732
Primary CNS Extranodal Marginal Zone B-Cell Lymphoma: A Case Series of 2 Patients Treated with External Beam Radiation Therapy
Primary CNS extranodal marginal zone B-cell lymphoma (MZBL) is a rare low-grade non-Hodgkin lymphoma characterized predominantly by small B cells, plasma cells, monocytoid cells, and scattered large immunoblasts. As a slow-growing tumor that remains localized, primary CNS MZBL carries an excellent clinical prognosis. Here, we report two cases of primary CNS MZBL successfully treated using external beam radiation therapy along with a literature review.
- 21 May 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (2) , 725-732
Open AccessPrimary CNS Extranodal Marginal Zone B-Cell Lymphoma: A Case Series of 2 Patients Treated with External Beam Radiation Therapy
Primary CNS extranodal marginal zone B-cell lymphoma (MZBL) is a rare low-grade non-Hodgkin lymphoma characterized predominantly by small B cells, plasma cells, monocytoid cells, and scattered large immunoblasts. As a slow-growing tumor that remains localized, primary CNS MZBL carries an excellent clinical prognosis. Here, we report two cases of primary CNS MZBL successfully treated using external beam radiation therapy along with a literature review.
- Open Access
- 11 May 2021
- Published by SAGE Publications in Bladder Cancer
- Vol. 7 (3) , 279-284
Differences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy
PURPOSE: Sex-specific differences exist in muscle invasive bladder cancer (MIBC): men have a higher incidence; women present with more advanced disease; and surgical options differ between men and women. Health related quality of life (HRQoL) for male versus female patients with MIBC is not well understood and limited data exists in patients who undergo bladder preservation with trimodality therapy (TMT). The purpose of this study was to compare long-term HRQoL between men and women who have undergone TMT. METHODS AND MATERIALS: This was a secondary analysis of a prior study that reported long-term HRQoL differences for patients who underwent TMT. We analyzed patient reported HRQoL data to assess differences in HRQoL between men and women. RESULTS: Of the 64/74 (86%) TMT patients that completed questionnaires, 14 (22%) were women. Median age at diagnosis was 60 years for women and 66 years for men ( p = 0.007). From six HRQoL instruments, there were two responses with a statistically significant difference between women and men –incidence of diarrhea and degree of sexual activity. Fifty percent of women compared to 86%of men reported no diarrhea ( p = 0.02). A greater percentage of women reported some degree of sexual activity in the 4 weeks prior to questionnaire completion ( p = 0.04), and sexual interest following TMT declined significantly with age in men, but not in women. CONCLUSIONS: In general, men and women report very good long-term HRQoL following TMT. There were, however, some differences between the sexes. Understanding this difference, especially related to sexual function, will allow more informed decision making by patients when choosing between treatment modalities.
- 11 May 2021
- Published by SAGE Publications in Bladder Cancer
- Vol. 7 (3) , 279-284
Open AccessDifferences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy
PURPOSE: Sex-specific differences exist in muscle invasive bladder cancer (MIBC): men have a higher incidence; women present with more advanced disease; and surgical options differ between men and women. Health related quality of life (HRQoL) for male versus female patients with MIBC is not well understood and limited data exists in patients who undergo bladder preservation with trimodality therapy (TMT). The purpose of this study was to compare long-term HRQoL between men and women who have undergone TMT. METHODS AND MATERIALS: This was a secondary analysis of a prior study that reported long-term HRQoL differences for patients who underwent TMT. We analyzed patient reported HRQoL data to assess differences in HRQoL between men and women. RESULTS: Of the 64/74 (86%) TMT patients that completed questionnaires, 14 (22%) were women. Median age at diagnosis was 60 years for women and 66 years for men ( p = 0.007). From six HRQoL instruments, there were two responses with a statistically significant difference between women and men –incidence of diarrhea and degree of sexual activity. Fifty percent of women compared to 86%of men reported no diarrhea ( p = 0.02). A greater percentage of women reported some degree of sexual activity in the 4 weeks prior to questionnaire completion ( p = 0.04), and sexual interest following TMT declined significantly with age in men, but not in women. CONCLUSIONS: In general, men and women report very good long-term HRQoL following TMT. There were, however, some differences between the sexes. Understanding this difference, especially related to sexual function, will allow more informed decision making by patients when choosing between treatment modalities.
- 21 April 2021
- Published by Elsevier in Clinical Oncology
- Vol. 33 (6) , e257-e263
Concomitant Systemic Therapy: Current and Future Perspectives
- 21 April 2021
- Published by Elsevier in Clinical Oncology
- Vol. 33 (6) , e257-e263
Concomitant Systemic Therapy: Current and Future Perspectives
- 16 April 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (5) , 1057-1065
Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria
This guideline for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) by the American Radium Society was developed by a multidisciplinary expert panel of medical, pediatric, and radiation oncologists convened to formulate guidelines for evaluation and treatment. The guideline development was based on an in-depth literature review and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of the recommendations by the panel. Given the scarcity of compelling data for strong recommendations for a rare lymphoma that has been shown to be more indolent than classical Hodgkin lymphoma, in instances where evidence is not available or equivocal, expert opinion guided the recommendations. Four clinical variants exemplify common scenarios and represent the consensus recommendations for patients with nodular lymphocyte Hodgkin lymphoma. A summary of the available published literature is also presented.
- 16 April 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (5) , 1057-1065
Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria
This guideline for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) by the American Radium Society was developed by a multidisciplinary expert panel of medical, pediatric, and radiation oncologists convened to formulate guidelines for evaluation and treatment. The guideline development was based on an in-depth literature review and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of the recommendations by the panel. Given the scarcity of compelling data for strong recommendations for a rare lymphoma that has been shown to be more indolent than classical Hodgkin lymphoma, in instances where evidence is not available or equivocal, expert opinion guided the recommendations. Four clinical variants exemplify common scenarios and represent the consensus recommendations for patients with nodular lymphocyte Hodgkin lymphoma. A summary of the available published literature is also presented.